Zacks Research Weighs in on Avanos Medical, Inc.’s Q4 2024 Earnings (NYSE:AVNS)

Avanos Medical, Inc. (NYSE:AVNS) – Equities researchers at Zacks Research cut their Q4 2024 earnings estimates for shares of Avanos Medical in a research note issued to investors on Thursday, May 23rd. Zacks Research analyst D. Dey now anticipates that the company will post earnings of $0.49 per share for the quarter, down from their previous estimate of $0.51. The consensus estimate for Avanos Medical’s current full-year earnings is $1.38 per share. Zacks Research also issued estimates for Avanos Medical’s Q3 2025 earnings at $0.52 EPS, Q4 2025 earnings at $0.56 EPS, FY2025 earnings at $1.81 EPS, Q1 2026 earnings at $0.49 EPS and FY2026 earnings at $2.27 EPS.

Several other research firms also recently weighed in on AVNS. StockNews.com upgraded shares of Avanos Medical from a “hold” rating to a “buy” rating in a report on Saturday, May 11th. JMP Securities reiterated a “market perform” rating on shares of Avanos Medical in a research report on Tuesday, May 7th.

Avanos Medical Stock Performance

Shares of AVNS stock opened at $19.96 on Friday. Avanos Medical has a 1 year low of $17.24 and a 1 year high of $26.56. The stock has a market cap of $916.16 million, a PE ratio of -15.01 and a beta of 0.97. The stock has a fifty day moving average price of $19.41 and a 200 day moving average price of $19.99. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.47 and a current ratio of 2.28.

Avanos Medical (NYSE:AVNS) last released its quarterly earnings data on Thursday, May 2nd. The company reported $0.19 EPS for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.02). Avanos Medical had a positive return on equity of 4.10% and a negative net margin of 9.15%. The company had revenue of $166.10 million for the quarter, compared to analysts’ expectations of $162.90 million. During the same period in the prior year, the firm posted $0.27 EPS. The firm’s quarterly revenue was up 4.3% on a year-over-year basis.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Avanos Medical by 2.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 20,722 shares of the company’s stock valued at $419,000 after acquiring an additional 504 shares during the last quarter. Gladius Capital Management LP lifted its stake in shares of Avanos Medical by 63.0% in the 4th quarter. Gladius Capital Management LP now owns 2,416 shares of the company’s stock valued at $54,000 after purchasing an additional 934 shares in the last quarter. Swiss National Bank grew its holdings in shares of Avanos Medical by 1.1% during the 3rd quarter. Swiss National Bank now owns 102,500 shares of the company’s stock worth $2,073,000 after purchasing an additional 1,100 shares during the period. Illinois Municipal Retirement Fund increased its position in Avanos Medical by 4.5% during the 4th quarter. Illinois Municipal Retirement Fund now owns 29,084 shares of the company’s stock worth $652,000 after purchasing an additional 1,262 shares in the last quarter. Finally, First National Bank of Omaha increased its position in Avanos Medical by 4.5% during the 4th quarter. First National Bank of Omaha now owns 29,956 shares of the company’s stock worth $672,000 after purchasing an additional 1,285 shares in the last quarter. Institutional investors and hedge funds own 95.17% of the company’s stock.

Insider Activity at Avanos Medical

In other news, CFO Michael Greiner sold 8,000 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $19.12, for a total transaction of $152,960.00. Following the sale, the chief financial officer now owns 151,495 shares in the company, valued at $2,896,584.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.90% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.